KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Raw Materials (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Raw Materials for 14 consecutive years, with $31.8 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 186.09% to $31.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.8 million through Dec 2025, up 186.09% year-over-year, with the annual reading at $31.8 million for FY2025, 186.09% up from the prior year.
  • Raw Materials for Q4 2025 was $31.8 million at Supernus Pharmaceuticals, down from $57.0 million in the prior quarter.
  • The five-year high for Raw Materials was $57.0 million in Q3 2025, with the low at $7.3 million in Q4 2021.
  • Average Raw Materials over 5 years is $18.8 million, with a median of $16.1 million recorded in 2023.
  • The sharpest move saw Raw Materials plummeted 73.5% in 2022, then soared 392.51% in 2025.
  • Over 5 years, Raw Materials stood at $7.3 million in 2021, then skyrocketed by 238.84% to $24.8 million in 2022, then crashed by 34.43% to $16.3 million in 2023, then tumbled by 31.63% to $11.1 million in 2024, then surged by 186.09% to $31.8 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $31.8 million, $57.0 million, and $8.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.